Literature DB >> 20848403

Utility of TL-201 SPECT in clarifying false-positive FDG-PET findings due to osteoradionecrosis in head and neck cancer.

Chih-Hsiu Wang1, Ji-An Liang, Hueisch-Jy Ding, Shih-Neng Yang, Kuo-Yang Yen, Shung-Shung Sun, Chia-Hung Kao.   

Abstract

BACKGROUND: This study aimed to determine whether Tl-201 single photon emission CT (SPECT) is potentially useful in differentiating false-positive fluorodeoxyglucose positron emission tomography (FDG-PET) findings caused by osteoradionecrosis (ORN) from recurrent head and neck cancer after radiotherapy.
METHODS: Five patients were recruited. Dual-phase FDG-PET and dual-phase Tl-201 SPECT were performed for each patient.
RESULTS: All 5 patients proved to have ORN without recurrent cancer. By visual interpretation, the results were 4 positive versus 1 negative for PET, and 4 negative versus 1 positive for Tl-201 SPECT. The Tl-201 SPECT clarified 3 of the 4 false-positive PETs to be ORN. Dual-phase semiquantitative studies showed decreased standardized uptake value (SUV) over time in 3 of the 4 false-positive PETs and decreased lesion/background ratio over time in the false-positive Tl-201 SPECT.
CONCLUSION: The Tl-201 SPECT may help clarify suspected false-positive FDG uptake caused by ORN. Dual-phase FDG-PET and dual-phase Tl-201 SPECT may also have some value.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848403     DOI: 10.1002/hed.21377

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  Positive and Negative Predictive Value of PET-CT in Skull Base Lesions: Case Series and Systematic Literature Review.

Authors:  John Peyton Hines; Brittany E Howard; Joseph M Hoxworth; Devyani Lal
Journal:  J Neurol Surg Rep       Date:  2016-03

Review 2.  Lumbar vertebral osteoradionecrosis: a rare case report with 10-year follow-up and brief literature review.

Authors:  Cong Jin; Minghua Xie; Wengqing Liang; Yu Qian
Journal:  BMC Musculoskelet Disord       Date:  2020-01-04       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.